[go: up one dir, main page]

JO3570B1 - صيغ للإعطاء بالفم من ديفيرازيروكس - Google Patents

صيغ للإعطاء بالفم من ديفيرازيروكس

Info

Publication number
JO3570B1
JO3570B1 JOP/2014/0075A JOP20140075A JO3570B1 JO 3570 B1 JO3570 B1 JO 3570B1 JO P20140075 A JOP20140075 A JO P20140075A JO 3570 B1 JO3570 B1 JO 3570B1
Authority
JO
Jordan
Prior art keywords
deferasirox
oral formulations
disclosure
orally administered
relates
Prior art date
Application number
JOP/2014/0075A
Other languages
English (en)
Inventor
Ghosh Indrajit
Jia-Ai, (Allen) Zhang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50288212&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3570(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of JO3570B1 publication Critical patent/JO3570B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/148—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بالكشف عن صيغ قابلة للإعطاء بالفم من ديفيرازيروكس حيث يشتمل على إطلاق منخفض تحت ظروف المعدة وإطلاق سريع بالقرب من الرقم الهيدروجيني pH المتعادل أو عند الرقم الهيدروجيني pH المتعادل.
JOP/2014/0075A 2013-03-08 2014-03-06 صيغ للإعطاء بالفم من ديفيرازيروكس JO3570B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361774893P 2013-03-08 2013-03-08
US201361824435P 2013-05-17 2013-05-17

Publications (1)

Publication Number Publication Date
JO3570B1 true JO3570B1 (ar) 2020-07-05

Family

ID=50288212

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0075A JO3570B1 (ar) 2013-03-08 2014-03-06 صيغ للإعطاء بالفم من ديفيرازيروكس

Country Status (42)

Country Link
US (4) US9283209B2 (ar)
EP (2) EP3124018B2 (ar)
JP (3) JP6434429B2 (ar)
KR (2) KR101925671B1 (ar)
CN (1) CN105025886B (ar)
AP (1) AP2015008668A0 (ar)
AU (2) AU2014224198B2 (ar)
BR (1) BR112015021254A2 (ar)
CA (1) CA2890465A1 (ar)
CL (1) CL2015002495A1 (ar)
CR (1) CR20150467A (ar)
CU (1) CU24348B1 (ar)
CY (2) CY1120021T1 (ar)
DK (2) DK3124018T3 (ar)
DO (1) DOP2015000220A (ar)
EA (1) EA031719B1 (ar)
EC (1) ECSP15042897A (ar)
ES (2) ES2708955T5 (ar)
HK (1) HK1212242A1 (ar)
HR (2) HRP20180387T1 (ar)
HU (2) HUE041224T2 (ar)
IL (1) IL240797B (ar)
JO (1) JO3570B1 (ar)
LT (2) LT2964202T (ar)
ME (1) ME03297B (ar)
MX (1) MX361055B (ar)
MY (1) MY170303A (ar)
NI (1) NI201500126A (ar)
NZ (1) NZ711179A (ar)
PE (1) PE20151600A1 (ar)
PH (1) PH12015501981B1 (ar)
PL (2) PL3124018T3 (ar)
PT (2) PT2964202T (ar)
RS (2) RS58317B1 (ar)
SA (1) SA515360425B1 (ar)
SG (2) SG10201807204YA (ar)
SI (2) SI3124018T1 (ar)
TN (1) TN2015000393A1 (ar)
TW (2) TWI625136B (ar)
UY (1) UY35367A (ar)
WO (1) WO2014136079A1 (ar)
ZA (1) ZA201506060B (ar)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2708955T5 (es) 2013-03-08 2023-11-10 Novartis Ag Formulaciones orales de deferasirox
US9866684B2 (en) * 2015-02-16 2018-01-09 Microsoft Technology Licensing, Llc Process for real-time data exchange between users on a phone call
WO2016167729A1 (en) * 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
AU2016280280B2 (en) * 2015-06-17 2021-09-02 AustinPx, LLC Improved formulations of deferasirox and methods of making the same
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
CA3029543C (en) * 2016-07-05 2021-11-23 Jubilant Generics Limited Immediate release pharmaceutical composition of iron chelating agents
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
CZ2017255A3 (cs) * 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
TR201707764A2 (tr) * 2017-05-29 2018-12-21 Biofarma Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasiroksun bölünebilir tablet formları.
WO2019108156A1 (en) * 2017-11-28 2019-06-06 Biofarma Ilac Sanayi Ve Ticaret A.S. A scored tablet formulation comprising deferasirox in a film tablet form
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
EP4052698A1 (en) * 2021-03-05 2022-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Film coated tablet comprising deferasirox
CN115154428B (zh) * 2022-09-06 2023-01-10 上海奥科达医药科技股份有限公司 一种地拉罗司药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW533205B (en) * 1996-06-25 2003-05-21 Novartis Ag Substituted 3,5-diphenyl-l,2,4-triazoles and their pharmaceutical composition
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
KR20070022243A (ko) * 2004-04-08 2007-02-26 노파르티스 아게 데페라시록스 분산성 정제
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
CA2625112A1 (en) * 2005-10-19 2007-04-26 Novartis Ag Dispersible tablets comprising deferasirox
US20090142395A1 (en) * 2007-11-19 2009-06-04 Uri Zadok Deferasirox pharmaceutical compositions
WO2009106824A2 (en) 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
EP2291360A2 (en) * 2008-04-21 2011-03-09 Actavis Group PTC ehf. Solid state forms of deferasirox salts and process for the preparation thereof
WO2010035282A1 (en) 2008-09-24 2010-04-01 Matrix Laboratories Limited Pharmaceutical compositions comprising deferasirox
WO2010143006A1 (en) 2009-06-10 2010-12-16 Carlo Ghisalberti Orally bioavailable iron chelators in the treatment of an inflammatory bowel disease
EP2929877A1 (en) * 2010-07-08 2015-10-14 ratiopharm GmbH Oral dosage form of deferasirox
AP3578A (en) 2010-10-01 2016-02-08 Cipla Ltd Pharmaceutical composition comprising deferasirox
ES2708955T5 (es) 2013-03-08 2023-11-10 Novartis Ag Formulaciones orales de deferasirox
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox

Also Published As

Publication number Publication date
US20180221285A1 (en) 2018-08-09
RS58317B1 (sr) 2019-03-29
SG11201506491RA (en) 2015-09-29
CU24348B1 (es) 2018-05-08
ME03297B (me) 2019-07-20
HRP20190173T1 (hr) 2019-03-22
AU2014224198B2 (en) 2017-06-15
NI201500126A (es) 2015-11-18
ES2708955T3 (es) 2019-04-12
EP3124018A1 (en) 2017-02-01
JP6434429B2 (ja) 2018-12-05
TWI686215B (zh) 2020-03-01
CY1120021T1 (el) 2018-12-12
HK1212242A1 (en) 2016-06-10
TWI625136B (zh) 2018-06-01
PL2964202T3 (pl) 2019-04-30
AU2014224198A1 (en) 2015-09-10
IL240797A0 (en) 2015-10-29
MY170303A (en) 2019-07-17
CN105025886A (zh) 2015-11-04
WO2014136079A1 (en) 2014-09-12
ZA201506060B (en) 2016-12-21
JP2016510068A (ja) 2016-04-04
NZ711179A (en) 2018-07-27
LT2964202T (lt) 2019-02-11
AU2017203897A1 (en) 2017-06-29
BR112015021254A2 (pt) 2017-07-18
HUE041224T2 (hu) 2019-05-28
PH12015501981A1 (en) 2016-01-11
EA031719B1 (ru) 2019-02-28
PT3124018T (pt) 2018-03-22
SA515360425B1 (ar) 2018-01-21
US20160220493A1 (en) 2016-08-04
ES2663135T5 (en) 2024-12-16
PT2964202T (pt) 2019-02-06
PH12015501981B1 (en) 2016-01-11
DOP2015000220A (es) 2015-11-30
EP3124018B2 (en) 2024-04-24
SG10201807204YA (en) 2018-09-27
TW201838623A (zh) 2018-11-01
HUE036921T2 (hu) 2018-08-28
CR20150467A (es) 2015-10-27
DK2964202T3 (en) 2019-02-25
EP3124018B1 (en) 2017-12-20
MX361055B (es) 2018-11-26
PE20151600A1 (es) 2015-11-26
ES2708955T5 (es) 2023-11-10
EP2964202B1 (en) 2018-10-31
ECSP15042897A (es) 2019-03-29
ES2663135T3 (es) 2018-04-11
CU20150110A7 (es) 2016-04-25
EA201591665A1 (ru) 2015-12-30
UY35367A (es) 2014-10-31
JP6739470B2 (ja) 2020-08-12
LT3124018T (lt) 2018-03-12
CN105025886B (zh) 2019-01-15
EP2964202B2 (en) 2023-05-31
DK3124018T3 (en) 2018-03-26
SI3124018T1 (en) 2018-04-30
US20170290811A1 (en) 2017-10-12
IL240797B (en) 2022-01-01
US20150017241A1 (en) 2015-01-15
AP2015008668A0 (en) 2015-08-31
HRP20180387T1 (hr) 2018-04-20
KR20170045391A (ko) 2017-04-26
KR20150126900A (ko) 2015-11-13
CY1121315T1 (el) 2020-05-29
JP2020180123A (ja) 2020-11-05
KR101925671B1 (ko) 2019-02-27
MX2015011962A (es) 2016-07-07
SI2964202T1 (sl) 2019-02-28
CL2015002495A1 (es) 2016-03-04
PL3124018T3 (pl) 2018-05-30
US9283209B2 (en) 2016-03-15
AU2017203897B2 (en) 2019-02-14
CA2890465A1 (en) 2014-09-12
TW201442742A (zh) 2014-11-16
JP2018162255A (ja) 2018-10-18
EP2964202A1 (en) 2016-01-13
RS56890B1 (sr) 2018-04-30
TN2015000393A1 (en) 2017-01-03

Similar Documents

Publication Publication Date Title
JO3570B1 (ar) صيغ للإعطاء بالفم من ديفيرازيروكس
HUE059662T2 (hu) Eljárás terápiás immunsejtek hatékonyságának fokozására
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
EP3174874A4 (en) BERBERINSALZE, URSODEOXYCHOLSALZE AND COMBINATIONS, METHOD FOR THE PRODUCTION AND THE APPLICATION THEREOF
DK3244878T3 (da) Faste orale sammensætningsformer
HK1254555A1 (zh) 修飾釋放口服給藥的氨基酸製劑
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
DK3307239T3 (da) Formuleringer til indgivelse af RSV- og norovirusantigener i tyndtarmen
EP3322451A4 (en) ELECTROCHEMICAL REDUCTION OR PREVENTING INFECTIONS
EP3394099A4 (en) Formulations of Manipulated Anti- IL-10 Antibodies
DK3411008T3 (da) Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren
HUE050377T2 (hu) Kovasav alapú antimikrobiális orális készítmények
EP3171860C0 (en) SOLID ORAL FORMULATION OF FENRETINIDE
IN2014DN06617A (ar)
EP3319980A4 (en) FORMULATIONS FOR IMPROVING THE EFFECTIVENESS OF HYDROPHOBIC DRUGS
EP3387469A4 (en) ELEKTROFAZIENBESTIMMUNG
MA39411A (fr) Synthèse de l'énantiomère de la progestérone et ses intermédiaires
DK3107568T3 (da) Formuleringer til indgivelse til tyndtarmen
EP3361867A4 (en) MOSQUITO ACTIVATION FORMULATIONS
EP3348148A4 (en) METHOD FOR THE SEPARATION OF POLYPHENOLEN YELLOW PITAHAYA (SELENICEREUS MEGALANTHUS)
ITUB20153699A1 (it) Integratore orale
EA201791596A1 (ru) Пиразоловые соединения
TR201910467T4 (tr) Selektif PYY bileşikleri ve bunların kullanımları.
FR3057727B1 (fr) Compression optimisee d'entete ip-v6
MA47193A (fr) Formes posologiques solides d'inhibiteurs bace1 2-amino-6-(difluorométhyl)-5,5-difluoro-6-phényl-3,4,5,6-tétrahydropyridine